Cargando…

Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain

We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mata-Cases, Manel, Casajuana, Marc, Franch-Nadal, Josep, Casellas, Aina, Castell, Conxa, Vinagre, Irene, Mauricio, Dídac, Bolíbar, Bonaventura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047944/
https://www.ncbi.nlm.nih.gov/pubmed/26542160
http://dx.doi.org/10.1007/s10198-015-0742-5
_version_ 1782457503048531968
author Mata-Cases, Manel
Casajuana, Marc
Franch-Nadal, Josep
Casellas, Aina
Castell, Conxa
Vinagre, Irene
Mauricio, Dídac
Bolíbar, Bonaventura
author_facet Mata-Cases, Manel
Casajuana, Marc
Franch-Nadal, Josep
Casellas, Aina
Castell, Conxa
Vinagre, Irene
Mauricio, Dídac
Bolíbar, Bonaventura
author_sort Mata-Cases, Manel
collection PubMed
description We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-015-0742-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5047944
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50479442016-10-18 Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain Mata-Cases, Manel Casajuana, Marc Franch-Nadal, Josep Casellas, Aina Castell, Conxa Vinagre, Irene Mauricio, Dídac Bolíbar, Bonaventura Eur J Health Econ Original Paper We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-015-0742-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-11-05 2016 /pmc/articles/PMC5047944/ /pubmed/26542160 http://dx.doi.org/10.1007/s10198-015-0742-5 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Mata-Cases, Manel
Casajuana, Marc
Franch-Nadal, Josep
Casellas, Aina
Castell, Conxa
Vinagre, Irene
Mauricio, Dídac
Bolíbar, Bonaventura
Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title_full Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title_fullStr Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title_full_unstemmed Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title_short Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
title_sort direct medical costs attributable to type 2 diabetes mellitus: a population-based study in catalonia, spain
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047944/
https://www.ncbi.nlm.nih.gov/pubmed/26542160
http://dx.doi.org/10.1007/s10198-015-0742-5
work_keys_str_mv AT matacasesmanel directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT casajuanamarc directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT franchnadaljosep directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT casellasaina directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT castellconxa directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT vinagreirene directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT mauriciodidac directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain
AT bolibarbonaventura directmedicalcostsattributabletotype2diabetesmellitusapopulationbasedstudyincataloniaspain